Ir al contenido
cube4devcube4dev
Descubrir y buscar Contacto
ES
DeutschEnglishEspañolFrançaisItaliano简体中文日本語
Minimal Organization: MERIVAN PHARMA, Pharmaunternehmen – das Gelände im Modell von schräg oben

Simulación · Minimal Organization · Industry

Pharmaceutical company

A pharmaceutical plant as a walkable model: follow a batch from the cleanroom to certification by the qualified person and see where the four weeks go.

Iniciar con contraseñaSolicitar la contraseña si le interesa →

Every figure for MERIVAN PHARMA is invented and the processes are simplified. Fitted to your site, the model can show what is scattered across systems today – such as live batch status from your batch records or test duration per method in the QC lab.

How does the pharma batch release process work, step by step? This page shows it at MERIVAN PHARMA, a fictional pharmaceutical company. Every batch is tested on its own and certified personally by one person. The diagram ‘Where the time goes’ shows how much of the four weeks goes into testing and review.

The path of a batch: supply chain schedules it, quality control tests the starting materials in quarantine, production manufactures in the cleanroom, fills and serialises, sterility test and final testing run in parallel, quality assurance reviews the batch record and the qualified person releases it. Target in the model: released within four weeks.

Process analytics and real-time release shorten exactly the part spent on testing and review. Alongside manufacturing, the model runs a first clinical trial, a marketing authorisation and a quality defect report. It shows processes as a model and is not regulatory or GMP advice. It is written for site management, quality, people development and communications.

A batch is made and released

  1. 01

    Schedule the batch: Supply chain schedules a batch of prefilled syringes with an anticoagulant.

  2. 02

    Test starting materials (quarantine): QC tests the starting materials; until then they are in quarantine.

  3. 03

    Manufacture in the cleanroom: Manufacture in the cleanroom to instruction, every step documented.

  4. 04

    Assess the deviation: QA assesses the deviation.

  5. 05

    Fill, pack, serialise: Filling, packing, every pack gets a unique number.

  6. 06

    Sterility test and final test run in parallel.

  7. 07

    Sterility test (14-day incubation): Samples incubate fourteen days.

  8. 08

    Final test: assay, purity: Assay and purity are measured.

  9. 09

    Tested.

  10. 10

    Batch record review: QA reviews the batch record.

  11. 11

    Qualified person releases: The qualified person certifies the batch personally.

  12. 12

    Dispatch to wholesale: Dispatch via the store to wholesale, temperature documented.

  13. 13

    In the market.

How a pharmaceutical company can use the model

  • Internal communication

    Research, preclinical, plant, quality, regulatory affairs and drug safety on one site. The org chart puts the qualified person in quality assurance next to production, both reporting straight to the board.

    Para quiénBoard, communications, all divisions

  • Onboarding

    New staff walk the path of a batch: quarantine, cleanroom, serialisation, testing, record review, release. They see why every step is documented and who takes over when.

    Para quiénNew staff in production, QC, QA and supply chain

  • Training

    Apprentices and students trigger ‘Contamination in the cleanroom’ or ‘API shortage’ and watch batches pile up before testing. ‘How a case flows’ teaches the mandatory steps of every batch.

    Para quiénPharma and chemistry apprentices, students, graduate trainees

  • Explaining to partners and the public

    Wholesalers, pharmacies and visitor groups see why weeks pass between manufacture and dispatch: incubation, final testing, record review and personal certification.

    Para quiénSales, communications, visitor groups

  • Strategic overview

    ‘What each control does’ sets real-time release, more QC analysts and a second API supplier side by side. A critical GMP inspection finding shows what a month at half speed in QA costs.

    Para quiénBoard, site management, quality

What is shown – why – for whom

Qué se muestra Por qué Para quién
Diagram ‘Where the time goes’ for one batch Por quéshows how much of the four weeks goes into testing and review Para quiénSite management, quality assurance
Diagram ‘What each control does’: real-time release, QC analysts, second API supplier Por quéranks the levers for faster release Para quiénManagement, quality
Diagram ‘How a case flows’: deviation, sterility test, release Por quéshows the mandatory steps of every batch Para quiénTraining, inspection readiness
Diagram ‘Who leads whom’: the qualified person in quality assurance Por quéshows that release is independent Para quiénBoard, authorities
Diagram ‘What the work depends on’: batch records and labs Por quéshows what a system outage sets off Para quiénIT, quality
Resources view in the QC lab Por quéshows the testing backlog before release Para quiénLab management
Process ‘A drug enters its first trial’ Por quéshows research next to manufacturing Para quiénResearch, investors

Departments in the model

  • Board

    Decides on the portfolio.

  • Drug discovery

    Finds candidates.

  • Preclinical

    Pharmacology and toxicology under GLP.

  • Clinical development

    Plans and steers trials in three phases.

  • Drug safety

    Collects and assesses side effects.

  • Regulatory affairs

    Dossier and agency contact.

  • Market access

    Benefit dossier, reimbursement price.

  • Sales

    Doctors and hospitals.

  • Supply chain

    Plans batches, runs the store.

  • Production (GMP)

    Manufactures to instruction in the cleanroom.

  • Quality control

    Tests starting materials and product.

  • Quality assurance

    Assesses deviations, reviews documentation.

  • Qualified person

    Releases every batch personally – a statutory role.

All processes in the model

A batch is made and released

  1. 01Schedule the batch: Supply chain schedules a batch of prefilled syringes with an anticoagulant.
  2. 02Test starting materials (quarantine): QC tests the starting materials; until then they are in quarantine.
  3. 03Manufacture in the cleanroom: Manufacture in the cleanroom to instruction, every step documented.
  4. 04Assess the deviation: QA assesses the deviation.
  5. 05Fill, pack, serialise: Filling, packing, every pack gets a unique number.
  6. 06Sterility test and final test run in parallel.
  7. 07Sterility test (14-day incubation): Samples incubate fourteen days.
  8. 08Final test: assay, purity: Assay and purity are measured.
  9. 09Tested.
  10. 10Batch record review: QA reviews the batch record.
  11. 11Qualified person releases: The qualified person certifies the batch personally.
  12. 12Dispatch to wholesale: Dispatch via the store to wholesale, temperature documented.
  13. 13In the market.

A drug enters its first trial

  1. 01Clinical trial application: Clinical development applies for the first trial in humans.
  2. 02Agency and ethics committee assess in parallel.
  3. 03Assessment by the agency: The federal agency checks safety and plan.
  4. 04Assessment by the ethics committee: The ethics committee checks participant protection.
  5. 05Approved.
  6. 06Patients are enrolled: Hospitals enrol participants.
  7. 07Trial runs: The trial runs, managed by a contract research organisation.
  8. 08Biostatistics analyses: Biostatistics analyses: on to the next phase?
  9. 09Stopped.
  10. 10Continue.

A medicine is authorised

  1. 01Marketing authorisation dossier: Regulatory affairs compiles the dossier: all trials, all data.
  2. 02Assessment, inspection and ramp run in parallel.
  3. 03Assessment: 210 days plus questions: The agency assesses: 210 active days, plus questions with the clock stopped.
  4. 04Pre-approval inspection: The state authority inspects the plant.
  5. 05Production ramp: Production ramps up.
  6. 06Positive opinion.
  7. 07EU Commission decision: The EU Commission decides on authorisation.
  8. 08Benefit dossier: A benefit dossier for reimbursement is prepared.
  9. 09Benefit assessment (three months): The added benefit is assessed in three months, then the price is negotiated.
  10. 10On the market.

A quality defect is reported

  1. 01Report from a pharmacy: A pharmacy reports: particles are floating in syringes from one batch.
  2. 02Risk assessment by QA and the safety officer: QA and the safety officer assess the risk.
  3. 03Inform the state authority: The state authority is informed.
  4. 04Recall via wholesale: The recall runs via wholesale to the pharmacies.
  5. 05Root cause and corrective action: Find the cause, introduce corrective actions.
  6. 06Closed.

What you can change

Controls

  • Production plan: More batches: QC and QA reach their limit.
  • QC analysts: How many tests run at once.
  • Process analytics and real-time release: Measurements during manufacture shorten tests and review (model assumption).
  • Second API supplier: Fewer deviations in starting materials (model assumption).

Disruptions

  • Critical GMP inspection finding: For a month QA and the qualified person work at half speed: everything is checked twice.
  • API shortage: For a month incoming tests take twice as long.
  • Contamination in the cleanroom: For two weeks only half of manufacturing runs.
  • Batch record system fails: For two hours no batch can be scheduled.

What the model offers a pharmaceutical company

  • 01

    Testing time you can see

    Fourteen days of incubation, final testing and record review appear as separate blocks in the diagram. Everyone sees why a batch is never done faster than its testing.

  • 02

    Levers side by side

    Real-time release, more analysts or a second supplier: the controls act on the running simulation at once, and the diagrams recalculate live.

  • 03

    Research and plant in one picture

    Research tower, preclinical unit, cleanroom block, QC lab and the high-bay store with cold room are walkable buildings. Trial, authorisation and quality defect run alongside manufacturing.

  • 04

    Disruptions without risk

    Cleanroom contamination, an API shortage or a batch record outage can be triggered and observed – in the model, not on the shop floor.

  • 05

    For lobbies and conferences

    The simulation runs in the browser and on large projections. A demo mode plays everything by itself and hands over as soon as someone takes the controls.

Basis and limits

Fictional pharmaceutical company · model based on researched industry structures · no forecast for real companies

1 case = 1 batch, 1 trial, 1 authorisation or 1 report · 1 figure ≈ 30 employees

All volumes, durations, rates and capacities are model assumptions, not values of a real company.

The path from candidate to medicine is reduced to a first trial and authorisation; in reality it takes ten to thirteen years.

Documented: release of every batch by the qualified person, sterility test, assessment by agency and ethics, 210 days plus questions at the agency, benefit assessment in three months.

Public sources the model is based on:

  • Arzneimittelgesetz (u. a. §§ 13, 63a)
  • EU-GMP-Leitfaden (EudraLex Band 4)
  • Europäische Arzneimittel-Agentur: zentrales Verfahren
  • Gemeinsamer Bundesausschuss: Nutzenbewertung
  • VO (EU) 536/2014 klinische Prüfungen

Your plant as a model

We fit the model to your processes, from incoming inspection to release. Write or call us; access to the simulation is protected by a password, which we share on request.

Iniciar con contraseña

Solicitar la contraseña si le interesa →

Preguntar sobre esto

Minimal Organization: Pharmaunternehmen

Los datos van solo a este sitio y sirven únicamente para responderle.

Similar business models

← Minimal Organization

Every figure for MERIVAN PHARMA is invented and the processes are simplified. Fitted to your site, the model can show what is scattered across systems today – such as live batch status from your batch records or test duration per method in the QC lab.